(Q34382555)

1 August 2017

1 reference

title

Rhabdomyolysis and HMG-CoA reductase inhibitors (English)

1 reference

1 August 2017

1 reference

M A Omar

1

1 reference

1 August 2017

J P Wilson

series ordinal

2

1 reference

1 August 2017

T S Cox

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Annals of Pharmacotherapy

1 August 2017

published in

1 reference

1 August 2017

volume

35

1 reference

1 August 2017

issue

9

1 reference

1 August 2017

page(s)

1096-1107

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 August 2017

cites work

1 reference

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

21 January 2018

1 reference

A comparative review of the adverse effects of treatments for hyperlipidaemia

21 January 2018

1 reference

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

21 January 2018

1 reference

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

21 January 2018

1 reference

Efficacy and tolerability of simvastatin (MK-733).

21 January 2018

1 reference

Current perspectives on statins

21 January 2018

1 reference

Rhabdomyolysis with simvastatin use

21 January 2018

1 reference

Found down: compartment syndrome, rhabdomyolysis, and renal failure

21 January 2018

1 reference

Efficacy and long-term adverse effect pattern of lovastatin

21 January 2018

1 reference

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

'Fire and forget?' - pharmacological considerations in coronary care

21 January 2018

1 reference

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

21 January 2018

1 reference

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

21 January 2018

1 reference

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

21 January 2018

1 reference

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

21 January 2018

1 reference

Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs

21 January 2018

1 reference

Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency

21 January 2018

1 reference

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

21 January 2018

1 reference

Lovastatin-induced acute rhabdomyolysis

21 January 2018

1 reference

Case of the month: February 1999--54 year old man with severe muscle weakness

21 January 2018

1 reference

Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine

21 January 2018

1 reference

Rhabdomyolysis and simvastatin

21 January 2018

1 reference

Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

21 January 2018

1 reference

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

21 January 2018

1 reference

Rhabdomyolysis due to interaction of simvastatin with mibefradil

21 January 2018

1 reference

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

21 January 2018

1 reference

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

21 January 2018

1 reference

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

21 January 2018

1 reference

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

21 January 2018

1 reference

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.10228

1 reference

1 August 2017

1 reference